Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-transplant Events

Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia

Bone Marrow Transplantation volume 43, pages 813–816 (2009)Cite this article

Abstract

We reviewed the incidence and risk factors for EBV-related post-transplant lymphoproliferative disorder (EBV-PTLD) in 89 patients with acquired aplastic anaemia (AAA) receiving allogeneic transplants between 1989 and 2006. The overall incidence of EBV-PTLD was 6.3% (5/89) with no cases in those receiving an allograft for constitutional BM failure syndromes (n=30) during the same period. There was no impact of age, gender, donor status, CMV seropositivity, GVHD and graft cell dose on the occurrence of PTLD. Although both reduced intensity conditioning (RIC) and the prior use of antithymocyte globulin (ATG), as immunosuppressive therapy (IST), were identified as the risk factors for PTLD, only prior use of ATG strongly influenced the development of PTLD with an incidence of 13.38±5.6% (5/43), compared with none in those not exposed to ATG before transplantation (P=0.01) with a relative risk of 10.39 for each course of prior ATG. This is the first study in patients with AAA documenting that those receiving multiple prior courses of ATG are at the highest risk of developing EBV-PTLD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Gupta V, Ball SE, Yi QL, Sage D, McCann SR, Lawler M et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Marrow Transplant 2004; 10: 867–876.

    Article  CAS  PubMed  Google Scholar 

  2. Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007; 109: 3219–3224.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Tichelli A, Passweg J, Nissen C, Bargetzi M, Hoffmann T, Wodnar-Filipowicz A et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol 1998; 100: 393–400.

    Article  CAS  PubMed  Google Scholar 

  4. Chakrabarti S, Milligan DW, Pillay D, Mackinnon S, Holder K, Kaur N et al. Reconstitution of the Epstein–Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003; 102: 839–842.

    Article  CAS  PubMed  Google Scholar 

  5. Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA et al. Marked increased risk of Epstein–Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108: 2874–2880.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Loren AW, Porter DL, Stadtmauer EA, Tsai DE . Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003; 31: 145–155.

    Article  CAS  PubMed  Google Scholar 

  7. Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo MA, Calore E et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005; 128: 224–233.

    Article  PubMed  Google Scholar 

  8. Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K . Post-transplant lymphoproliferative disease and other Epstein–Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis 2007; 39: 235–244.

    Article  CAS  PubMed  Google Scholar 

  9. Cohen JM, Cooper N, Chakrabarti S, Thomson K, Samarasinghe S, Cubitt D et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma 2007; 48: 256–269.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology and Stem Cell Transplantation, St George's Hospital, London, UK

    H C E Buyck, S Ball, P Junagade, J Marsh & S Chakrabarti

  2. Department of Haematology, St George's University of London, London, UK

    S Ball, J Marsh & S Chakrabarti

Authors
  1. H C E Buyck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Ball
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Junagade
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Marsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Chakrabarti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Chakrabarti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buyck, H., Ball, S., Junagade, P. et al. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant 43, 813–816 (2009). https://doi.org/10.1038/bmt.2008.394

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.394

Keywords

This article is cited by

Search

Advanced search

Quick links